Cure8 regulatory brief
Researchers are exploring a gut microbe–derived lipid (SoL A) that may reduce inflammation relevant to IBD. If development succeeds, it could point to new, microbiome-based therapeutic approaches for people with Crohn’s disease or ulcerative colitis.
Researchers studying microbiome therapies, immunology, and IBD drug discovery; clinicians interested in emerging preclinical IBD therapeutics; patients and caregivers curious about microbiome-based research and future treatment directions.
This NIH Reporter project record describes a funded Phase I STTR project to test the feasibility of developing a microbial-derived sulfonolipid (SoL A) as an anti-inflammatory agent with IBD as a prototype disease.
The summary reports prior observational and experimental work linking decreased SoL production (from genera such as Alistipes and Odoribacter) with IBD, in vitro macrophage assays indicating SoLs modulate TLR4/LPS-driven inflammation, and methods to induce bacteria to overproduce and purify SoLs.
The proposed Phase 1 aims are toxicity/PK testing in cells and mice and efficacy testing in two mouse colitis models (piroxicam-accelerated Il10-/- and DSS-induced colitis). The project record is a research funding summary, not clinical results or an approved therapy.
It outlines planned preclinical safety and efficacy studies intended to provide proof-of-concept and a Go/No-Go decision for further development.
Findings described are from prior preclinical work and the proposed Phase 1 project aims; this record does not present completed human clinical data. The project focuses on proof-of-concept in cell and mouse models as the next development step.
Review the original publication for the complete reporting, methods, and context.
Funding disclosed by the source: National Center for Complementary and Integrative Health - R41AT013357 - $399,494
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Researchers are exploring a way to deliver biologic drugs directly in the gut using engineered B cells that become long-lived plasma cells. If successful, this could allow sustained, localized anti-inflammatory protein...
This project explores how gut microbes and bile acids interact to shape immune cells in the ileum — a process that may affect inflammation in Crohn’s disease and other IBDs. Understanding these mechanisms could point to...
The study suggests a probiotic strain (Lactobacillus plantarum) reduced inflammation and prolonged remission in multiple mouse models of Crohn’s-like disease, indicating microbiome-based approaches might be promising to...
